Physician profile
Victor Bui
NPI 1871187443
$20,085.42
in general payments reported to CMS, 2019-2025
33 companies · $5,259 in 2025
The $5,259 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,706 · 2022: $4,012 · 2023: $4,614 · 2024: $4,495 · 2025: $5,259.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $1.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,365.93 |
| Education | $1.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $2,453.65 | 2021-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $2,170.54 | 2021-2025 | Rexulti, Abilify Mycite, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,606.38 | 2021-2025 | Caplyta |
| Abbvie INC. | $1,578.51 | 2021-2025 | |
| Alkermes, INC. | $1,547.87 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $1,534.57 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $1,115.80 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Vanda Pharmaceuticals INC. | $1,043.81 | 2022-2025 | Fanapt, Hetlioz |
| Supernus Pharmaceuticals, INC. | $915.00 | 2021-2025 | Qelbree |
| Lundbeck LLC | $911.81 | 2021-2025 | Rexulti |
| Axsome Therapeutics, INC. | $854.67 | 2022-2025 | Auvelity |
| Corium, LLC | $848.32 | 2021-2024 | Azstarys, Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $678.74 | 2021-2025 | Trintellix |
| Tris Pharma INC | $448.43 | 2022-2025 | Onyda Xr, Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $432.28 | 2024-2025 | Cobenfy |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $349.67 | 2021-2022 | |
| Indivior INC. | $325.15 | 2022-2024 | Perseris |
| Ironshore Pharmaceuticals INC. | $320.67 | 2022-2023 | Jornay Pm |
| Neos Therapeutics, LP | $199.53 | 2022-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt |
| Tempus Ai, INC | $177.53 | 2024-2025 | Tempus Pixel, Tempus Pixel |
| Owp Pharmaceuticals, INC. | $81.20 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $80.91 | 2024 | Nuplazid |
| Idorsia Pharmaceuticals US INC | $76.54 | 2022-2023 | Quviviq |
| Eisai INC. | $73.04 | 2021-2022 | |
| Luye Pharma (USA) LTD. | $44.80 | 2025 | Erzofri Extended-Release |
| Noven Therapeutics, LLC | $40.95 | 2023-2024 | Xelstrym, Secuado |
| Boston Scientific Corporation | $40.24 | 2025 | General - Pain Management |
| Validus Pharmaceuticals LLC | $25.91 | 2023 | Equetro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.51 | 2024 | |
| Bausch Health US, LLC | $23.89 | 2022 | |
| Sage Therapeutics, LLC | $23.75 | 2024 | |
| Almatica Pharma LLC | $21.33 | 2025 | Loreev Xr |
| Vertical Pharmaceuticals, LLC | $15.42 | 2025 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Bui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.